Accera, Inc. is a privately-held, development stage company focused on the development and commercialization of innovative therapeutics to treat central nervous system disorders. The company is pioneering a novel therapeutic approach to meet the needs of patients with neurodegenerative diseases where metabolic deficiencies have been established. The company has an experienced world-class CNS development team and is backed by a group of committed investors including Nestle Health Sciences.
Accera’s lead product, AC-1204, is the first proprietary Alzheimer’s disease (AD) therapy that addresses the recognized physiological hallmark of the AD brain’s inability to optimally metabolize glucose (hypometabolism) by providing an alternative energy source for brain cells. AC-1204 is currently undergoing Phase 3 development in mild to moderate Alzheimer’s Disease patients.
Accera is evaluating AC-1204 and other agents in additional CNS indications where metabolic deficiencies is an issue.